See other companies on Otta
Deciphex
Preclinical pathology software
- 101-200 employees
- Healthcare
- B2B
- Artificial Intelligence
- Productivity
- Deep Tech
- Machine Learning
- SaaS
- MedTech
- DCU Alpha Building, Innovation Campus, 11 Old Finglas Rd, Glasnevin, Co. Dublin
Jump to section
Company mission
Deciphex's mission is to enable users to facilitate digital peer review of non-clinical pathology studies.
Otta's take
Xav Kearney
CTO of Otta
Pathologists are the core of diagnostics, but have been under increasing pressure in recent years with cancer cases rising, diagnostic complexity increasing, and the number of pathologists in decline. This systemic strain has meant turnaround times for diagnoses are longer, and the chance of diagnostic error is higher. Deciphex is looking to help address this, starting with its flagship regulated non-clinical pathology platform Patholytix.
Deciphex has institutional and headline support, is supported as a High Potential Startup by Ireland, has collaborated with AstraZeneca and Janssen, and participates in a research program with pharmaceutical company Charles River. Reports suggest the platform has seen impressive uptake in the preclinical sector, so in spite of being relatively young this specialist niche is in high demand.
This all means Deciphex is in a strong position to keep expanding out its suite of tools and platforms and, with Ireland’s lively and well-funded MedTech scene, the company has found no problems securing financial support. Its latest round of funding will go towards increasing headcount and expanding its presence across territories, as well as fuelling further research and development.
Benefits
- Cutting Edge Technology Space
- Multi Cultural, Diverse Team
- Autonomy & Trust in Your Role
- A Commitment to Flexible Working Arrangements
- Continued Learning and Development Opportunities
- Social Events
- Competitive Annual Leave
Company values
- Supportive - We know working together will bring success.
- Diverse - We value our differences, skills, and perspectives.
- Challenging - We're confident, innovative, and forward-thinking, and we're always learning.
- Innovtive - We aim high and won’t let anything stand in our way of achieving our goals.
Funding (last 2 of 10 rounds)
Jan 2023
$4.3m
LATE VC
May 2022
$11.5m
SERIES B
$27.6m
Total funding
Founders
Donal O’Shea
(Chief Executive)Has experience founding three companies prior to Deciphex, and has senior management experience in Slidepath, Genetix, Leica Microsystems and Leica Biosystems.
Jobs (2)
Software Engineering